Share

Pharm Fresh: What Pharmacological Solutions Could Play a Role in Preventing Diabetes?

EN_11_2023_COVER (002) For decades, physicians have maintained that type 2 diabetes could be delayed or even prevented altogether simply by modifying certain behaviors. Priyanka Majety, MD, talks to Endocrine News about pharmacological options that could help these patients, but lifestyle modifications are still crucial. As we enter National Diabetes Month and head toward World Diabetes Day on...
Share

Special Treatment: Highlighting Cutting-Edge Diabetes Tech

Cutting-edge advancements in endocrinology continue to move diabetes treatment in the right direction faster than ever before. The treatment of diabetes is continually evolving. More than a century ago, a diabetes diagnosis was a death sentence, and although there is not yet a cure, endless updates in diabetes care help ease the burden of both...
Share

Pharma Fridays – November 10

Zepbound_Logo_PNG An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves Lilly’s Zepbound™ (tirzepatide) for Chronic Weight Management On November 8, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide)...
Share

FDA Approves Lilly’s Zepbound™ (tirzepatide) for Chronic Weight Management

On November 8, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Zepbound is indicated for adults with obesity (with a BMI of 30 kg/m2 or greater), or those who...
Share

Software Company Simplifies Glycemic Management for Clinicians and Pharmacists

In August, the insulin management software company Glytec unveiled the latest version of its Glucommander insulin dosing software to make it easier for providers, nurses, and pharmacists to offer optimal, personalized care. More than 300 hospitals in the U.S. use Glytec’s eGlycemic Management System® (eGMS®) for glycemic management for their patients. Glytec chief medical officer...
Share

Good Sports

winning with diabetes cover A new book spotlights athletes thriving with diabetes. In the new book, Winning with Diabetes: Inspiring Stories from Athletes to Help You Thrive, Rita R. Kalyani, MD, MHS; Mark D. Corriere, MD; and Patrick Smith have created an inspirational handbook that clinicians can share with their patients to help them overcome the challenges they may...
Share

Pharma Fridays – November 3, 2023

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information.* New Clinical Data Point to Use of GlycoMark as Biomarker of SGLT-2 Diabetes Drug Effectiveness and Compliance Precision Diabetes, Inc. announces new studies that show that the GlycoMark blood test, which measures 1,5-anhydroglucitol, may be useful for evaluating short-term effectiveness and assessing...